
Glimitoss MP 2mg/500mg/15mg Tablet SR
Marketer
Minitoss Medicines
Salt Composition
Glimepiride (2mg) + Metformin (500mg) + Pioglitazone (15mg)
Overview Glimitoss MP 2mg/500mg/15mg Tablet SR
Glucotrim Trio 2mg/500mg/15mg Extended-Release Tablets combine three medications to manage blood glucose. This regimen, used alongside diet and exercise, enhances blood sugar control in adult patients with type 2 diabetes. It facilitates efficient insulin use, consequently reducing blood sugar. Always adhere to your physician's prescribed dosage and frequency for Glucotrim Trio 2mg/500mg/15mg ER Tablets; take with food to minimize gastrointestinal distress. If a dose is missed, take it promptly unless the next dose is imminent; in that case, omit the missed dose and resume your usual schedule. Never double the dose. Overdosage can result in hypoglycemia (low blood sugar). Concurrent use with other diabetes medications, alcohol, or skipped meals may increase hypoglycemia risk; regular blood glucose monitoring is crucial. Common adverse effects may include nausea, diarrhea, abdominal pain, headache, bone fractures, and respiratory infections. Prior to commencing treatment, inform your doctor of any kidney, liver, or heart conditions. Pregnant or lactating individuals require medical consultation before use. Kidney function tests will be assessed before treatment initiation. Limit alcohol consumption as this might exacerbate side effects.
Uses of Glimitoss MP 2mg/500mg/15mg Tablet SR
Managing type 2 diabetes
Major Benefits of Glimitoss MP 2mg/500mg/15mg Tablet SR:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the entire tablet without chewing, crushing, or breaking it. Glimitoss MP 2mg/500mg/15mg Sustained-Release Tablets should be taken with meals.
Common Side effects of Glimitoss MP 2mg/500mg/15mg Tablet SR:
- Hypoglycemia (low blood glucose level)
- Headache
- Nausea
- Diarrhea
- Dizziness
- Vomiting
- Anemia (low number of red blood cells)
- Weakness
- Sinus infection
How to use Glimitoss MP 2mg/500mg/15mg Tablet SR:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment schedule. Ingest the entire tablet without chewing, crushing, or fracturing it. The Glimitoss MP 2mg/500mg/15mg Extended-Release tablet should be taken with a meal.
How Glimitoss MP 2mg/500mg/15mg Tablet SR works:
Glimitoss MP 2mg/500mg/15mg Extended-Release Tablets combine glimepiride, metformin, and pioglitazone—three distinct antidiabetic agents. This triple-drug approach enhances blood sugar management when monotherapy or dual therapy proves insufficient. Glimepiride, a sulfonylurea, stimulates pancreatic insulin secretion to reduce blood glucose levels. Metformin, a biguanide, acts by decreasing hepatic glucose production, slowing intestinal glucose absorption, and improving insulin responsiveness. Pioglitazone, a thiazolidinedione, further augments insulin sensitivity.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent alcohol use with Glimitoss MP 2mg/500mg/15mg SR tablets is inadvisable.
PregnancyCONSULT YOUR DOCTOR
The use of Glimitoss MP 2mg/500mg/15mg SR tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the potential advantages against any possible risks prior to prescribing this medication. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Glimitoss MP tablets (2mg/500mg/15mg) are likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these blood sugar imbalances.
KidneyCAUTION
Patients with kidney impairment should use Glimitoss MP 2mg/500mg/15mg SR tablets cautiously, potentially requiring dosage modification. Consult a physician for guidance. Glimitoss MP 2mg/500mg/15mg SR tablets are contraindicated in individuals with severe kidney disease. Routine monitoring of kidney function is recommended during treatment.
LiverCAUTION
Patients with hepatic impairment should use Glimitoss MP 2mg/500mg/15mg Tablet SR cautiously, potentially requiring dosage modification. Physician consultation is advised. Glimitoss MP 2mg/500mg/15mg Tablet SR is contraindicated in patients exhibiting severe liver dysfunction.
What if you forget to take Glimitoss MP 2mg/500mg/15mg Tablet SR :
Should you forget a dose of Glimitoss MP 2mg/500mg/15mg Tablet SR, take it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Glimitoss MP 2mg/500mg/15mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
